INTELLIA THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities
INTELLIA THERAPEUTICS, INC. (NTLA) reported Increase (Decrease) in Accrued Liabilities of -$5.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.36M, a 663.94% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$11.95M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $9.03M, a 128.36% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$715.00K, a 111.50% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2025 was -$5.27M.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$10.38M, a 272.36% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $6.02M, a 62.17% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $15.92M, a 7.74% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 8 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.59M 10-Q · filed 2026-08-06 | $3.44M derived: sum of 3 quarters · filed 2026-08-06 | $2.72M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$11.95M 10-Q · filed 2026-05-11 | -$2.92M derived: sum of 2 quarters · filed 2026-05-11 | -$3.63M derived: sum of 3 quarters · filed 2026-05-11 | -$2.80M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $8.31M derived: sum of 2 quarters · filed 2026-02-26 | $9.14M derived: sum of 3 quarters · filed 2026-08-06 | -$5.27M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$715.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $117.00K derived: sum of 2 quarters · filed 2026-08-06 | -$14.30M 10-Q · filed 2025-11-06 | -$10.35M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $832.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$13.58M 10-Q · filed 2026-08-06 | -$9.63M derived: sum of 3 quarters · filed 2026-08-06 | -$3.41M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$14.41M 10-Q · filed 2026-05-11 | -$10.46M derived: sum of 2 quarters · filed 2026-05-11 | -$4.24M derived: sum of 3 quarters · filed 2026-05-11 | -$2.40M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.17M derived: sum of 2 quarters · filed 2026-02-26 | $12.02M derived: sum of 3 quarters · filed 2026-02-26 | -$10.38M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $6.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.07M derived: sum of 2 quarters · filed 2025-11-06 | -$14.34M 10-Q · filed 2025-11-06 | -$5.30M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$20.55M 10-Q · filed 2025-08-07 | -$11.52M derived: sum of 3 quarters · filed 2026-02-26 | -$2.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | -$22.40M 10-Q · filed 2025-05-08 | -$13.37M derived: sum of 2 quarters · filed 2026-02-26 | -$3.85M derived: sum of 3 quarters · filed 2026-02-26 | $1.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $18.55M derived: sum of 2 quarters · filed 2026-02-26 | $23.42M derived: sum of 3 quarters · filed 2026-02-26 | $6.02M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $9.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $14.38M derived: sum of 2 quarters · filed 2024-11-07 | -$3.01M 10-Q · filed 2024-11-07 | $64.00K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$12.53M 10-Q · filed 2024-08-08 | -$9.45M derived: sum of 3 quarters · filed 2025-02-27 | $4.12M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$17.39M 10-Q · filed 2024-05-09 | -$14.32M derived: sum of 2 quarters · filed 2025-02-27 | -$747.00K derived: sum of 3 quarters · filed 2025-02-27 | $2.25M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $16.64M derived: sum of 2 quarters · filed 2025-02-27 | $19.64M derived: sum of 3 quarters · filed 2025-02-27 | $15.92M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $13.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $16.57M derived: sum of 2 quarters · filed 2023-11-09 | $12.85M 10-Q · filed 2023-11-09 | $31.28M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$721.00K 10-Q · filed 2023-08-03 | $17.71M derived: sum of 3 quarters · filed 2024-02-22 | $6.40M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | -$3.72M 10-Q · filed 2023-05-04 | $14.71M derived: sum of 2 quarters · filed 2024-02-22 | $3.41M derived: sum of 3 quarters · filed 2024-02-22 | $18.13M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $18.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $7.13M derived: sum of 2 quarters · filed 2024-02-22 | $21.85M derived: sum of 3 quarters · filed 2024-02-22 | $17.26M 10-K · filed 2024-02-22 | |
| 2021-09-30 | -$11.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $3.42M derived: sum of 2 quarters · filed 2022-11-03 | -$1.17M 10-Q · filed 2022-11-03 | $5.14M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-06-30 | $14.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $10.13M 10-Q · filed 2022-08-04 | $16.45M derived: sum of 3 quarters · filed 2023-02-23 | $20.73M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2021-03-31 | -$4.59M 10-Q · filed 2022-05-05 | $1.72M derived: sum of 2 quarters · filed 2023-02-23 | $6.01M derived: sum of 3 quarters · filed 2023-02-23 | $8.27M derived: sum of 4 quarters · filed 2023-02-23 | |
| 2020-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $10.60M derived: sum of 2 quarters · filed 2023-02-23 | $12.85M derived: sum of 3 quarters · filed 2023-02-23 | $13.03M 10-K · filed 2023-02-23 | |
| 2020-09-30 | $4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $6.54M derived: sum of 2 quarters · filed 2021-11-04 | $6.72M 10-Q · filed 2021-11-04 | $7.99M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-06-30 | $2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.43M 10-Q · filed 2021-08-05 | $3.70M derived: sum of 3 quarters · filed 2022-02-24 | $3.80M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | $177.00K 10-Q · filed 2021-05-06 | $1.44M derived: sum of 2 quarters · filed 2022-02-24 | $1.54M derived: sum of 3 quarters · filed 2022-02-24 | $5.09M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2019-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.36M derived: sum of 2 quarters · filed 2022-02-24 | $4.92M derived: sum of 3 quarters · filed 2022-02-24 | $2.31M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.65M derived: sum of 2 quarters · filed 2020-11-05 | $1.04M 10-Q · filed 2020-11-05 | $2.40M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $3.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $947.00K 10-Q · filed 2020-08-06 | $2.30M derived: sum of 3 quarters · filed 2021-02-26 | $3.42M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | -$2.60M 10-Q · filed 2020-05-07 | -$1.25M derived: sum of 2 quarters · filed 2021-02-26 | -$130.00K derived: sum of 3 quarters · filed 2021-02-26 | $1.78M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $2.48M derived: sum of 2 quarters · filed 2021-02-26 | $4.39M derived: sum of 3 quarters · filed 2021-02-26 | $2.78M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $3.03M derived: sum of 2 quarters · filed 2019-10-31 | $1.42M 10-Q · filed 2019-10-31 | $3.52M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $305.00K 10-Q · filed 2019-08-01 | $2.40M derived: sum of 3 quarters · filed 2020-02-27 | $2.95M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2018-03-31 | -$1.61M 10-Q · filed 2019-05-02 | $483.00K derived: sum of 2 quarters · filed 2020-02-27 | $1.04M derived: sum of 3 quarters · filed 2020-02-27 | $2.68M derived: sum of 4 quarters · filed 2020-02-27 | |
| 2017-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $2.65M derived: sum of 2 quarters · filed 2020-02-27 | $4.29M derived: sum of 3 quarters · filed 2020-02-27 | $2.39M 10-K · filed 2020-02-27 | |
| 2017-09-30 | $554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $2.19M derived: sum of 2 quarters · filed 2018-10-31 | $302.00K 10-Q · filed 2018-10-31 | $1.61M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | -$252.00K 10-Q · filed 2018-08-01 | $1.06M derived: sum of 3 quarters · filed 2019-02-27 | $1.75M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$1.89M 10-Q · filed 2018-05-01 | -$584.00K derived: sum of 2 quarters · filed 2019-02-27 | $104.00K derived: sum of 3 quarters · filed 2019-02-27 | $1.29M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2016-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.00M derived: sum of 2 quarters · filed 2019-02-27 | $3.18M derived: sum of 3 quarters · filed 2019-02-27 | $3.05M 10-K · filed 2019-02-27 | |
| 2016-09-30 | $688.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $1.88M derived: sum of 2 quarters · filed 2017-10-31 | $1.74M 10-Q · filed 2017-10-31 | $1.33M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-06-30 | $1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $1.05M 10-Q · filed 2017-08-01 | $638.00K derived: sum of 3 quarters · filed 2018-03-14 | $1.35M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2016-03-31 | -$134.00K 10-Q · filed 2017-05-02 | -$549.00K derived: sum of 2 quarters · filed 2018-03-14 | $167.00K derived: sum of 3 quarters · filed 2018-03-14 | $1.23M derived: sum of 4 quarters · filed 2018-03-14 | |
| 2015-12-31 | -$415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $301.00K derived: sum of 2 quarters · filed 2018-03-14 | $1.37M derived: sum of 3 quarters · filed 2018-03-14 | $805.00K 10-K · filed 2018-03-14 | |
| 2015-09-30 | $716.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $1.78M derived: sum of 2 quarters · filed 2016-11-01 | $1.22M 10-Q · filed 2016-11-01 | ||
| 2015-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $504.00K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | -$561.00K 10-Q · filed 2016-06-03 | ||||
| 2014-12-31 | $1.06M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |